1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

29 May 2024
Admin
News Article

FDA Prioritizes Review of Sarclisa for Newly Diagnosed Multiple Myeloma Patients

FDA Prioritizes Review of Sarclisa for Newly Diagnosed Multiple Myeloma Patients Excluded from Transplant Eligibility

Overview

The U.S. Food and Drug Administration (FDA) has given priority review status to the Supplemental Biologics License Application (sBLA) for Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for treating newly diagnosed multiple myeloma patients ineligible for transplantation. This combination could potentially be the first of its kind, paving the way for a new treatment avenue for these patients. The FDA is expected to announce its decision on September 27, 2024. A similar submission is also being considered in the European Union (EU).

New First-Line Therapies

Sanofi, expressed confidence in Sarclisa's potential, stating that despite recent advancements, there's still a significant need for new first-line therapies, particularly for patients ineligible for transplantation.
He emphasized that the regulatory acceptance of their submissions and the priority review designation from the FDA reinforce their belief in Sarclisa's potential to advance multiple myeloma treatment.

Behind Approval

The application for supplemental license and EU approval is based on positive outcomes from the phase III clinical trial IMROZ.
This trial showed a statistically significant improvement in progression-free survival among newly diagnosed multiple myeloma patients ineligible for transplantation who received Sarclisa in combination with VRd chemotherapy compared to those treated with VRd alone.
Safety assessments indicated consistency with established safety profiles.

IMROZ Trial

The IMROZ trial is the fourth phase III investigation of Sarclisa paired with VRd chemotherapy in newly diagnosed multiple myeloma patients ineligible for transplantation.
The results of this trial will be presented at major congresses.

Priority Review Designation

Priority review designation is given to drug applications with the potential to significantly advance the treatment of serious diseases.

The IMROZ trial enrolled 446 patients across multiple centers globally. Patients received Sarclisa in combination with VRd chemotherapy until disease progression or unacceptable adverse events.

Sarclisa

Sarclisa is a monoclonal antibody targeting the CD38 receptor on multiple myeloma cells, inducing cytotoxic activities and immunomodulation.
Sarclisa has received approvals in multiple countries for various combinations in relapsed and refractory multiple myeloma patients. Its clinical development is ongoing in multiple myeloma and other cancers.

Multiple myeloma :- Multiple myeloma is a significant hematologic cancer with a high incidence rate and challenges in treatment and prognosis.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!